280 related articles for article (PubMed ID: 34370130)
1. Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.
Bird P; Littlejohn G; Butcher B; Smith T; O'Sullivan C; Witcombe D; Griffiths H
Clin Rheumatol; 2022 Jan; 41(1):53-62. PubMed ID: 34370130
[TBL] [Abstract][Full Text] [Related]
2. Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia.
Bird P; Littlejohn G; Butcher B; Smith T; da Fonseca Pereira C; Witcombe D; Griffiths H
Clin Rheumatol; 2020 Sep; 39(9):2545-2551. PubMed ID: 32157469
[TBL] [Abstract][Full Text] [Related]
3. Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.
Littlejohn G; Leadbetter J; Butcher BE; Feletar M; O'Sullivan C; Smith T; Witcombe D; Ng HY; Youssef P
Clin Rheumatol; 2024 May; 43(5):1579-1589. PubMed ID: 38459357
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
Harnett J; Gerber R; Gruben D; Koenig AS; Chen C
J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
[TBL] [Abstract][Full Text] [Related]
5. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Charles-Schoeman C; Burmester G; Nash P; Zerbini CA; Soma K; Kwok K; Hendrikx T; Bananis E; Fleischmann R
Ann Rheum Dis; 2016 Jul; 75(7):1293-301. PubMed ID: 26275429
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis.
Caporali R; Zavaglia D
Clin Exp Rheumatol; 2019; 37(3):485-495. PubMed ID: 30183607
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study.
Fisher A; Hudson M; Platt RW; Dormuth CR;
J Rheumatol; 2021 Jan; 48(1):16-24. PubMed ID: 33004534
[TBL] [Abstract][Full Text] [Related]
10. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
Mease PJ; Young P; Gruben D; Fallon L; Germino R; Kavanaugh A
Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248
[TBL] [Abstract][Full Text] [Related]
11. Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset.
Griffiths H; Smith T; Mack C; Leadbetter J; Butcher B; Acar M; Ciciriello S
J Rheumatol; 2022 Feb; 49(2):150-156. PubMed ID: 34334362
[TBL] [Abstract][Full Text] [Related]
12. Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years.
Pope J; Bessette L; Jones N; Fallon L; Woolcott J; Gruben D; Crooks M; Gold D; Haraoui B
Rheumatology (Oxford); 2020 Mar; 59(3):568-574. PubMed ID: 31410469
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
14. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy.
D'Alessandro F; Cazzato M; Laurino E; Morganti R; Bardelli M; Frediani B; Buongarzone C; Moroncini G; Guiducci S; Cometi L; Benucci M; Ligobbi F; Marotto D; Mosca M
Clin Rheumatol; 2024 Feb; 43(2):657-665. PubMed ID: 38135860
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.
Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindström U; Turesson C; Frisell T
Rheumatology (Oxford); 2022 Oct; 61(10):3952-3962. PubMed ID: 35134119
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.
Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H
Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400
[TBL] [Abstract][Full Text] [Related]
17. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
18. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
[TBL] [Abstract][Full Text] [Related]
19. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
Gabay C; Riek M; Scherer A; Finckh A;
Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
